CD47 and cancer: Importantly, resistance to PrCR induced by CD47-blockade has been described in several types of cancers, which is not attributable to the deficiency of CD47 expression on these cells nor the contribution of other known “don’t eat me” signals, suggesting the existence of additional anti-PrCR mechanisms (82–84).